Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

Alector, Inc. ALEC

Healthcare — Biotechnology

We limit data available in the Overview Report for users who do not have Powerpack

Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.
Register an account and get your Powerpack now or Login

Insider Decisions

Total sells
1.02
in millions of $
Nov 25 Feb 26 May 26 Aug 26
Buy — — — — — — — — — — — —
Sell — — 5 — 1 5 1 — 3 — — 3
Insider Ownership
25.95%

Capital & Financial Ratios

Market Cap
206.57
Revenue
13.86
Net Income
(117.85)
Free Cash Flow
(158.39)
Net Debt
(162.95)
Current Ratio
5.26
Debt/Equity
(0.99)
P/E ratio
0.00
P/S ratio
16.37
P/B ratio
0.00
Past 5Y EPS Growth
6.31%
This Y EPS Growth
38.03%
Next Y EPS Growth
18.74%
Next 5Y EPS Growth
18.30%
in millions of $

Dividends

Payout Ratio
0.00
Annual Dividend Rate
—
Annual Dividend Yield
—
total individual payouts
2025 ‡‡‡
2024 ‡‡‡
2023 ‡‡‡
2022 ‡‡‡
2021 ‡‡‡
2020 ‡‡‡
2019 ‡‡‡
2018 ‡‡‡
predictions in italic, special payouts not included in total or ratios

Assets vs Liabilities

2023 2024 2025 Q'26
Cash 548.86 413.40 256.02 172.80
Receivables — — — —
Inventory — — — —
Other — — — —
565.81 424.82 266.45 180.09
2023 2024 2025 Q'26
Payables 3.78 2.22 1.69 2.28
ST’ Debt — — 0.37 9.85
Other 39.44 48.63 11.45 —
177.95 125.06 69.50 34.24
in millions of $

Compound Annual Growth

10y 5y 3y
Sales — ‡‡‡‡‡ ‡‡‡‡‡
Cash Flow — ‡‡‡ ‡‡‡
Earnings — ‡‡‡ ‡‡‡
Book Value — ‡‡‡‡‡ ‡‡‡‡‡

Revenue

Mar Jun Sep Dec Year
’26 1.05 3.32 — —
—
’25 3.67 7.87 3.26 6.24
21.05
’24 15.89 15.08 15.34 54.24
100.56
’23 16.55 56.21 9.11 15.19
97.06
’22 24.47 79.85 14.85 14.44
133.62
’21 4.11 6.57 182.41 13.99
207.09
’20 7.17 3.17 5.90 4.85
21.10
in millions of $

Operating Cash Flow

Mar Jun Sep Dec Year
’26 (49.81) (34.22) — —
—
’25 (60.78) (49.05) (32.51) (41.69)
(184.03)
’24 (61.35) (62.80) (50.73) (55.03)
(229.90)
’23 (48.55) (43.00) (46.54) (46.07)
(184.16)
’22 135.09 (57.44) (49.05) (48.92)
(20.33)
’21 (52.69) (44.54) 445.05 (49.26)
298.55
’20 (32.31) (45.94) (40.82) (47.66)
(166.73)
in millions of $

Free Cash Flow

Mar Jun Sep Dec Year
’26 (49.93) (34.25) — —
—
’25 (60.80) (49.06) (32.52) (41.69)
(184.07)
’24 (61.88) (63.13) (50.95) (55.20)
(231.16)
’23 (49.57) (44.22) (46.45) (46.30)
(186.54)
’22 134.40 (58.19) (50.97) (49.69)
(24.45)
’21 (53.64) (45.37) 444.14 (49.82)
295.30
’20 (35.88) (46.24) (41.20) (48.45)
(171.77)
in millions of $

EPS

Mar Jun Sep Dec Year
’26 (0.21) (0.21) — —
—
’25 (0.41) (0.30) (0.34) (0.34)
(1.39)
’24 (0.38) (0.40) (0.43) (0.02)
(1.23)
’23 (0.55) 0.02 (0.53) (0.49)
(1.56)
’22 (0.54) 0.12 (0.56) (0.63)
(1.62)
’21 (0.66) (0.69) 1.49 (0.68)
(0.45)
’20 (0.53) (0.58) (0.67) (0.66)
(2.45)

Target Price Range

High
‡‡‡‡‡
‡‡‡
Average
‡‡‡‡‡
‡‡‡
Low
‡‡‡‡‡
‡‡‡

Recommendation Rating

2.9
1
Buy
2
3
Hold
4
5
Sell
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
— — — ‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ 6.85 3.66 1.68 0.87 — — —
Low Price
— — — ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 21.26 9.86 8.90 3.40 — — —
High Price
— — ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 273 244 238 103 — — —
Employees
‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.49 0.40 0.42 0.20 — — —
Revenue/Emp
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 133.62 97.06 100.56 21.05 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue
‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 100.00% 100.00% 100.00% 100.00% — — —
Gross Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (130.06) (125.18) (118.92) (142.76) — — —
EBT
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (97.33%) (128.97%) (118.26%) (678.36%) ‡‡‡ ‡‡‡ ‡‡‡
EBT Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (133.31) (130.39) (119.05) (142.93) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Net Income
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 7.31 (6.47) (5.54) 3.38 — — —
Depreciation
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1.62 1.16 1.04 0.20 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (1.62) (1.56) (1.23) (1.39) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Earnings/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.25) (2.20) (2.38) (1.79) ‡‡‡‡‡ — —
Cash Flow/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.05) (0.03) (0.01) 0.00 ‡‡‡ ‡‡‡ ‡‡‡
Capex/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.30) (2.23) (2.39) (1.79) — — —
Free CF/Sh
‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 2.60 1.60 1.31 0.30 ‡‡‡‡ — —
Book Value/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 82.47 83.73 96.59 103.00 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Shares
‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 0.00 0.00 0.00 0.00 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
PE Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 5.62 6.89 1.82 7.64 ‡‡‡ ‡‡‡ ‡‡‡
PS Ratio
‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 3.50 4.99 1.44 5.24 ‡‡‡ ‡‡‡ ‡‡‡
PB Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.61 1.65 (2.12) (4.07) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
EV/Sales
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (3.31) (0.86) 0.92 0.47 — — —
EV/FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (20.33) (184.16) (229.90) (184.03) ‡‡‡ ‡‡‡ ‡‡‡
Op' Cash Flow
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (4.12) (2.38) (1.25) (0.04) ‡‡‡‡‡ ‡‡‡‡‡ —
Capex
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (24.45) (186.54) (231.16) (184.07) ‡‡‡‡‡ — —
FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 632.63 387.86 299.76 196.95 — — —
Working Cap'
— — — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 43.33 — 9.39 9.69 — — —
Total Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (669.52) (548.86) (404.01) (246.33) — — —
Net Debt
‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 214.44 134.16 126.80 30.65 — — —
Sh' Equity
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (16.64%) (18.50%) (21.84%) (37.54%) — — —
ROA
‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 0.00% 0.00% 0.00% 0.00% — — —
ROIC
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (51.75%) (74.81%) (91.24%) (181.56%) — — —
ROE
predictions in italic, sparklines do not include predictions

Analyst Commentary (Summary)

Alector, Inc. (ALEC), a biotech innovator targeting Alzheimer’s and other neurodegenerative diseases with immuno-neurology therapies, is trading at rock-bottom levels amid brutal sector headwinds and macro squeezes like high interest rates choking funding. Revenue skyrocketed to $207 million in 2021 from big-pharma milestones like the GSK deal, but crashed over 50% since, with forecasts predicting an 83% plunge to $17 million in 2025—highlighting the lumpy, high-risk nature of biotech milestones and setbacks like the AL101 trial flop.

Deep losses persist ($119 million net loss in 2024), cash burn is accelerating, and insiders dumped over 772,000 shares with zero buys, fueling bearish vibes. Analysts see 33% downside on average, though Phase 3 AL002 data could flip the script for massive upside. A cash-rich balance sheet buys time, but dilution looms in this volatile arena.

Is ALEC a beaten-down bargain or a value trap? With neurodegeneration demand booming yet trials notoriously binary, this analysis unpacks the numbers to reveal if a turnaround is brewing—or more pain ahead. [Read the full analysis]

Read full commentary →

Alector, Inc. (ALEC) Latest News

News by impact score

Fine-tune

6 Aug

3 , 4:05 PM
Alector reported second quarter 2026 financial results and issued a business update. Quarterly financial results and business updates can moderately shift investor views on near-term performance.

9 Jul

4 www.biopharmadive.com, 7:45 AM
GSK terminates brain drug alliance with Alector, ending the collaboration on neurodegeneration programs. Loss of GSK partnership removes major funding and development support for Alector's core neurodegeneration pipeline.

18 Jun

3 , 8:18 PM
Alector (ALEC) stock encounters mixed analyst price target revisions tied to Tau therapy readthrough developments. Mixed analyst target shifts on Tau therapy readthrough indicate moderate effects on Alector market views and pipeline perception.

19 May

3 Simply Wall St., 12:34 AM
Alector's investment narrative is evolving with new emphasis on tau readthrough mechanisms and blood-brain barrier shuttle technologies that target neurodegenerative disease pathways. Tau readthroughs and BBB shuttles represent pipeline refinements that could influence Alector's competitive stance without guaranteeing immediate financial transformation.

7 May

3 Zacks, 7:05 PM
Alector (ALEC) reported a Q1 loss and revenue that fell short of analyst estimates. Q1 loss and revenue miss highlight weaker financial results, likely affecting short-term market sentiment and stock performance.

3 GlobeNewswire, 4:05 PM
Alector, Inc. (ALEC) reported first quarter 2026 financial results and provided a business update. Quarterly financial results and business updates moderately influence biotech firms' financial performance and investor sentiment.

3 Zacks, 10:00 AM
Alector (ALEC) faces likelihood of negative Q1 earnings, driven by Zacks Rank #4 (Sell), -73.91% Earnings ESP, and history of missing estimates, with key metrics like revenue and pipeline updates in focus. Potential Q1 earnings miss moderately impacts financial performance and investor sentiment for the biotech firm.

2 May

3 Simply Wall St., 9:19 PM
GSK navigates Alzheimer’s program setback and leadership change at partner Alector, Inc. (ALEC) while advancing other products. Alzheimer’s setback and leadership shift introduce moderate uncertainty balanced by product progress.

30 Apr

4 , 8:08 AM
Alector (ALEC) investor narrative shifts toward BBB shuttle programs and execution risks, highlighting progress in blood-brain barrier delivery tech amid challenges in clinical and operational delivery. Narrative pivot to core BBB shuttle platform and execution risks signals major strategic focus likely to reshape investor sentiment and long-term trajectory.

29 Apr

4 GlobeNewswire, 4:05 PM
Alector to discontinue Phase 2 PROGRESS-AD trial of nivisnebart (AL101/GSK4527226) in early Alzheimer’s disease after interim futility analysis showed unlikely achievement of primary endpoint. Discontinuing a partnered Phase 2 Alzheimer’s trial due to futility delivers major pipeline setback, threatening Alector’s clinical progress and stock valuation.

20 Mar

4 Simply Wall St., 7:04 PM
Alector (ALEC) investor narrative shifts positively as company intensifies focus on BBB shuttle technology to enhance brain-targeted therapies for neurodegenerative diseases. BBB shuttle emphasis marks a pivotal strategic shift strengthening Alector's immuno-neurology pipeline and market positioning.

4 Mar

3 Simply Wall St., 6:08 AM
Alector's investment narrative shifts as analysts revise price targets amid evolving sector perspectives. Analyst target revisions and sector view changes moderately influence Alector's market sentiment and performance trajectory.

3 Mar

3 www.marketbeat.com, 9:45 PM
Alector showcased its ABC brain-delivery platform and provided updates on AL137 and AL050 at the TD Cowen Conference. Showcasing brain-delivery platform and pipeline updates at a major healthcare conference signals progress in neurodegeneration programs, potentially influencing investor sentiment and competitive positioning.

25 Feb

4 , 4:05 PM
Alector, Inc. (ALEC) reported fourth quarter and full year 2025 financial results alongside a business update. Quarterly and annual earnings releases with business updates often drive significant shifts in stock price and investor outlook due to financial metrics and pipeline progress.

3 Zacks, 7:25 PM
Alector (ALEC) reported a Q4 net loss but beat revenue estimates. Q4 revenue beat despite loss moderately boosts investor sentiment on financial performance without altering long-term biotech trajectory.

3 , 4:19 PM
Alector, Inc. (ALEC) released Q4 earnings snapshot detailing quarterly financial results. Q4 earnings snapshots deliver key financial metrics influencing short-term market sentiment and performance moderately.

17 Feb

3 Simply Wall St.Simply Wall St., 9:10 PM
A new sector-driven price target reshapes Alector, Inc. (ALEC)'s investment story and valuation outlook. Sector-driven price target influences Alector's valuation narrative and investor sentiment moderately.

6 Feb

4 Simply Wall St., 4:38 AM
Alector, Inc. (ALEC) is highlighted among global market stocks with estimated value opportunities for February 2026. The analysis suggests that ALEC's innovative approaches in the biopharmaceutical sector may position it favorably for future growth, particularly in the context of increasing demand for neurological treatments. Investors are encouraged to consider ALEC as a potential candidate for long-term investment based on its strategic initiatives and market positioning. Alector's strategic initiatives and market positioning are likely to significantly impact its future performance and investor sentiment.

3 Feb

3 Simply Wall St., 5:10 PM
Alector, Inc. (ALEC) faces a narrative shift following its removal from a key index, prompting concerns about its market position. The company is now focusing on new therapeutic targets, which may influence investor sentiment and future performance. Analysts are closely monitoring these developments as they could impact Alector's strategic direction and financial outlook. The index removal and new targets may moderately influence Alector's market positioning and investor sentiment.

19 Jan

3 Simply Wall St., 7:11 PM
Alector, Inc. faces challenges following the setback of its drug Latozinemab, leading to significant cost-cutting measures. The company is reevaluating its strategy and focusing on its core pipeline to navigate these difficulties. Investors are concerned about the implications for future growth and market performance as Alector adjusts its operations in response to these setbacks. The setback of Latozinemab and subsequent cost cuts are expected to moderately influence Alector's financial performance and strategic direction.

12 Dec

3 GlobeNewswire, 4:05 PM
Alector, Inc. has appointed Neil Berkley as Chief Financial Officer and Chief Business Officer. Berkley brings extensive experience in finance and business development, having previously held senior roles at various biotech companies. His appointment is expected to strengthen Alector's financial strategy and business operations as the company advances its pipeline of immuno-neurology therapies. The appointment of a new CFO and CBO may influence Alector's financial performance and strategic direction, but the overall effect is expected to be somewhat limited.

5 Dec

4 Simply Wall St.ZacksAssociated Press FinanceZacksSimply Wall St.Simply Wall St.Simply Wall St.Simply Wall St., 4:08 PM
Alector, Inc. faced a significant setback following the failure of its Latozinemab trial, which aimed to treat Alzheimer's disease. The trial's results have shifted investor sentiment and raised concerns about the company's future prospects. Analysts are reevaluating Alector's pipeline and market position, as the failure may hinder its ability to attract partnerships and funding. The company is now under pressure to demonstrate progress in its other programs to regain investor confidence. The trial failure is likely to significantly impact Alector's future performance and investor sentiment, necessitating a strategic reevaluation.

21 Nov

4 Simply Wall St.ZacksBioPharma DiveSimply Wall St., 3:05 PM
Alector, Inc. faced a significant setback in its clinical trials, leading analysts to reassess the company's future prospects. The failure of a key study has raised concerns about the viability of its drug pipeline and overall strategy. Investors are reacting to the news, with stock performance reflecting uncertainty about Alector's ability to recover from this blow. Analysts are now cautious, adjusting their forecasts and expectations for the company's upcoming developments. The clinical setback is likely to significantly impact Alector's future performance and investor sentiment.

18 Nov

4 Zacks, 10:33 AM
Alector, Inc. (ALEC) has experienced a significant decline in stock value, plummeting 63% over the past month. This drop is attributed to disappointing clinical trial results for its Alzheimer's treatment, which failed to meet primary endpoints. The company is now facing increased scrutiny from investors and analysts regarding its future prospects and strategic direction. Alector's leadership has acknowledged the challenges and is exploring options to address the setbacks, but uncertainty remains about the company's ability to recover and regain investor confidence. Disappointing clinical trial results for a key product significantly impact Alector's future and market performance.

7 Nov

3 Simply Wall St., 2:13 PM
Alector, Inc. faced a significant setback in its clinical trials, leading to a reevaluation of its strategic direction and investor sentiment. The company's recent challenges have raised concerns about its future prospects and ability to innovate in the competitive biotech landscape. Analysts are closely monitoring the implications of these developments on Alector's pipeline and market position. The clinical setback is expected to moderately influence Alector's financial performance and competitive positioning.

6 Nov

3 Zacks, 6:25 PM
Alector, Inc. (ALEC) reported a loss for Q3 but exceeded revenue estimates. The company's financial results indicate ongoing challenges, yet the revenue performance suggests some resilience in its operations. Investors may view the revenue beat positively, despite the loss. The revenue beat indicates potential for improved financial performance, but the loss suggests ongoing challenges.

3 Associated Press Finance, 5:29 PM
Alector, Inc. reported its Q3 earnings, highlighting key financial metrics and developments in its pipeline. The company continues to focus on advancing its therapeutic candidates aimed at neurodegenerative diseases. Despite challenges, Alector remains committed to its strategic goals and is optimistic about future growth prospects. The earnings report indicates moderate progress in product development and financial performance, which may influence investor sentiment.

3 GlobeNewswire, 4:05 PM
Alector, Inc. reported its financial results for the third quarter of 2025, highlighting key metrics such as revenue, expenses, and net loss. The company provided updates on its clinical programs and strategic initiatives aimed at advancing its pipeline of therapies for neurodegenerative diseases. Alector emphasized its commitment to innovation and collaboration in the biotech sector, aiming to enhance shareholder value and drive future growth. The financial results and updates on clinical programs indicate a moderate influence on Alector's future performance and market sentiment.

31 Oct

4 Insider Monkey, 5:42 AM
Alector, Inc. announced topline results from its Phase 3 INFRONT-3 clinical trial evaluating Latozinemab for the treatment of Alzheimer's disease. The trial aimed to assess the drug's efficacy and safety in patients with early-stage Alzheimer's. Results indicated that Latozinemab met its primary endpoint, demonstrating a statistically significant reduction in clinical decline compared to placebo. Alector plans to submit these findings to regulatory authorities and continue its development efforts for Latozinemab as a potential treatment option. The successful Phase 3 trial results for Latozinemab could significantly impact Alector's market position and investor sentiment.

29 Oct

3 Zacks, 10:00 AM
Alector, Inc. (ALEC) is anticipated to report negative earnings for the third quarter, raising concerns among investors about the company's financial health. Analysts are closely monitoring the situation as the earnings release approaches, which could influence market sentiment and the company's stock performance. Negative earnings may moderately affect investor sentiment and financial performance.
© 2016–2026 stockrow.com Terms and Conditions Indicators Weekly Summary Contact Us